O. O’Connor, “Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in heavily pretreated patients with hematological malignancies”, Hematol Meeting Rep, vol. 1, no. 8, Jun. 2009.